Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Rebecca KristeleitVictor MorenoValentina BoniEva M GuerraCarmen KahattIgnacio RomeroEmiliano CalvoNeus BastéJosé A López-VilariñoMariano SigueroVicente AlfaroAli ZeaiterMartin ForsterPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)
In patients with recurrent advanced endometrial cancer treated with doxorubicin and lurbinectedin, response rates (42%) and duration of response (7.5 months) were favorable. Further evaluation of doxorubicin and lurbinectedin is warranted in this patient population.